Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

Archives

Author Archives: aarocaud
Jul 4, 2014AaronNews

ASX Announcement – Green Whistle receives regulatory approval in South Africa

Medical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in South Africa to market and sell its inhaled analgesic product, ‘Penthrox’  for pain relief from trauma and surgical procedures. The approval gives MVP’s partner in South Africa, LINK Healthcare Pte Ltd (through its wholly owned subsidiary Equity Pharmaceuticals Pty Ltd), […]

Read more
Oct 15, 2013AaronUncategorised

ASX Announcement: Acceptance of Marketing Authorisation Application for ‘The Green Whistle’ in Europe

Medical Developments International Limited (ASX:MVP) is delighted to announce it has lodged its Marketing Authorisation Application (MAA) in Europe and that it has been accepted for review by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom. Once approved, Penthrox will be available for sale in the UK, France, Belgium and Ireland. The […]

Read more
Sep 11, 2013AaronNews

ASX Announcement – Successful Clinical Study Results

?THOROUGH QT/QTc? PENTHROX? CLINICAL TRIAL SUCCESSFULLY MEETS ALL PRIMARY AND SECONDARY OBJECTIVES

Medical Developments International Limited (ASX:MVP) is delighted to announce it has completed the
Thorough QT/QTc Clinical Trial.

Read more
Jan 21, 2013AaronNews

ASX Announcement

20 January 2013 ASX ANOUNCEMENT RESULTS OF PIVOTAL PHASE III CLINICAL TRIAL Methoxyflurane inhalation demonstrated to be highly effective analgesic. Methoxyflurane provided clinically-significant pain reduction. Demonstrated safety of methoxyflurane for the treatment of acute pain. Primary Endpoint and Objective of the study was met. All Secondary Endpoints and Objectives were met. MVP Comment Medical Developments […]

Read more
Oct 30, 2012AaronNews

ASX Announcement

2012 Annual General Meeting Address to Shareholders by Chairman and CEO 24 October, 2012 ADDRESS BY CHAIRMAN MR. DAVID WILLIAMS Last year I reported that our changed approach to the business allowed us to achieve a NPAT of $1.74 million for FY11. This year we recorded a record NPAT of $2.72 million. All shareholders want […]

Read more
Aug 23, 2012AaronNews

CHAIRMAN’S AND CEO’S REPORT

CONTINUING GROWTH AND RECORD PROFIT Medical Developments International Limited. (MDI) (ASX:MVP) delivered a Record Net Profit After Tax of $2,704,024 for the year ended 30 June 2012, which represents a 55% increase on FY2011 ($1,743,270).  MDI finished the year with $3.5 million of cash reserves after paying $2.7 million on clinical trials and two 3 […]

Read more
Aug 6, 2012AaronNews

LAST PATIENT ENROLLED: EUROPEAN PHASE III PIVOTAL TRIAL COMPLETED

Medical Developments International Limited (ASX: MVP) is delighted to confirm the 300th and final patient has been enrolled into its European Phase III trial. The trial commenced in August of 2011 and has successfully completed on time and on budget. The Phase III trial is a randomized, double blind, multi-centre, placebo controlled study to evaluate […]

Read more
Apr 13, 2012AaronNews

DRP Results

Medical Developments is delighted to confirm the following results from its Interim Dividend declared on 23 February, 2012. 64% of shareholders chose to reinvest in shares in the company rather than take a cash dividend.  The remaining shareholders were paid the Internim Dividend of 3 cents on 11 April, 2012. The CEO Mr John Sharman […]

Read more

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter